We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+35.97%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.08B
AUM Growth
+$343M
Cap. Flow
+$210M
Cap. Flow %
19.51%
Top 10 Hldgs %
30.46%
Holding
99
New
30
Increased
28
Reduced
17
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$29M
2
INSM icon
Insmed
INSM
+$26.6M
3
HUM icon
Humana
HUM
+$22.7M
4
CYTK icon
Cytokinetics
CYTK
+$19.3M
5
CRSP icon
CRISPR Therapeutics
CRSP
+$15.7M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$19.9M
2
TFX icon
Teleflex
TFX
+$17.5M
3
NTRA icon
Natera
NTRA
+$13.2M
4
ZBH icon
Zimmer Biomet
ZBH
+$12.2M
5
LLY icon
Eli Lilly
LLY
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THC icon
1
Tenet Healthcare
THC
$21.1B
$44.7M 4.15%
425,000
+75,000
+21% +$6.74M
BSX icon
2
Boston Scientific
BSX
$69.2B
$41.1M 3.81%
600,000
+225,000
+60% +$14.5M
VKTX icon
3
Viking Therapeutics
VKTX
$3.91B
$36.9M 3.43%
450,000
-50,000
-10% -$2.22M
INSM icon
4
Insmed
INSM
$21.5B
$35.3M 3.27%
1,300,000
+950,000
+271% +$26.6M
CYTK icon
5
Cytokinetics
CYTK
$10.7B
$31.5M 2.93%
450,000
+250,000
+125% +$19.3M
MRK icon
6
Merck
MRK
$317B
$31M 2.88%
+235,000
New +$29M
EHC icon
7
Encompass Health
EHC
$11B
$28.9M 2.68%
350,000
+100,000
+40% +$7.32M
WBA
8
DELISTED
Walgreens Boots Alliance
WBA
$28.2M 2.62%
1,300,000
+200,000
+18% +$4.44M
ELV icon
9
Elevance Health
ELV
$84.8B
$25.9M 2.41%
50,000
+30,000
+150% +$14.9M
VKTX icon
10
PUT
Viking Therapeutics
VKTX
$3.91B
$24.6M 2.28%
+300,000
New +$13.3M
ABBV icon
11
AbbVie
ABBV
$435B
$24.6M 2.28%
135,000
-35,000
-21% -$6.03M
UHS icon
12
Universal Health Services
UHS
$10.4B
$22.8M 2.12%
125,000
+55,000
+79% +$9.08M
NVS icon
13
Novartis
NVS
$294B
$21.8M 2.02%
225,000
– –
TARS icon
14
Tarsus Pharmaceuticals
TARS
$2.67B
$21.4M 1.99%
590,000
+490,000
+490% +$14.4M
LBPH
15
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$21.1M 1.95%
975,000
+75,000
+8% +$1.64M
HUM icon
16
Humana
HUM
$43.7B
$20.8M 1.93%
+60,000
New +$22.7M
NBIX icon
17
Neurocrine Biosciences
NBIX
$16.4B
$20.7M 1.92%
150,000
+60,000
+67% +$8.19M
BRKR icon
18
Bruker
BRKR
$7.99B
$20.7M 1.92%
220,000
+120,000
+120% +$9.65M
ISRG icon
19
Intuitive Surgical
ISRG
$133B
$20M 1.85%
50,000
+10,000
+25% +$3.78M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$19.9M 1.85%
210,000
+70,000
+50% +$6M
ACLX
21
DELISTED
Arcellx
ACLX
$17.7M 1.65%
255,000
+95,000
+59% +$6.02M
CRL icon
22
Charles River Laboratories
CRL
$12.6B
$17.6M 1.63%
65,000
– –
REGN icon
23
Regeneron Pharmaceuticals
REGN
$79.1B
$16.4M 1.52%
17,000
-8,000
-32% -$7.61M
RGNX icon
24
Regenxbio
RGNX
$672M
$16M 1.49%
760,000
+435,000
+134% +$7.74M
PEN icon
25
Penumbra
PEN
$12.7B
$15.6M 1.45%
70,000
+30,000
+75% +$7.42M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Integral Health Asset Management held 99 positions worth $1.08B, up 47% from $734M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Integral Health Asset Management deployed $210M of net new capital in Q1 2024, opening 30 new positions and adding to 28 existing holdings. Its largest new stake was Merck: 235,000 shares worth $31M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier.

On the sell side, the largest reduction was Natera, an estimated $13.2M trimmed.

  • Integral Health Asset Management's largest Q1 2024 buy was Merck: 235,000 shares worth $31M.
  • Integral Health Asset Management added most to Insmed in Q1 2024, an estimated $26.6M increase.
  • Integral Health Asset Management's biggest Q1 2024 reduction was Natera, cutting an estimated $13.2M.
  • Integral Health Asset Management fully exited Sanofi in Q1 2024, selling an estimated $19.9M.
  • Integral Health Asset Management's ten largest holdings make up 30% of its $1.08B portfolio in Q1 2024.
  • Integral Health Asset Management opened 30 new positions and closed 19 in Q1 2024.
  • Integral Health Asset Management's portfolio value rose 47% quarter-over-quarter to $1.08B.

Based on Integral Health Asset Management's 13F filing for Q1 2024, filed 15 May 2024.